- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01532544
Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis
Double-blinded, Randomized Trial in Severe Pneumonia Patients With Severe Sepsis Investigating the Safety and Efficacy of Co-administration of Iloprost and Ascending Doses of Eptifibatide Compared to Low-molecular-weight Heparin
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 18 years of age AND
Suspected or proven bacterial pneumonia requiring administration of antibiotics:
- Clinical diagnosis of pneumonia, (i.e. new or increased cough, production of purulent sputum or a change in the character of sputum in subjects who normally have purulent sputum, typical auscultatory findings of pneumonia on chest examination) and:
- chest radiograph or CT within the last 24 hr showing a pulmonary infiltrate.
- Dyspnea and/or tachypnea (>20 breaths/minute) or mechanical ventilation
Two or more systemic inflammatory response syndrome (SIRS) criteria within the last 24 hours:
- Temperature </= 36˚ C or >/= 38˚C
- Heart rate >/= 90 beats per minute
- Mechanical ventilation for acute respiratory process or respiratory rate >/= 20 breaths per minute or PaC02 < 4.2 kPa
- WBC >/= 12,000/mm³ OR </= 4,000/mm³ OR > 10% bands
- At least one organ failure beyond respiratory failure (cerebral, cardiovascular, hepatic, renal or coagulation within the last 24 hours (> 2 in SOFA score for the specific organ system) AND
- Can be randomized into trial and dosed < 48 h after severe sepsis diagnosis AND
- Consent is obtainable -
Exclusion Criteria:
- Patient is pregnant or breast-feeding
- Patient weigh more than 125 kg
- Patients with known allergy towards any of the investigational products or contraindications which should be excluded according to the investigational product specifications
- Investigators clinical decision deeming study participation not favourable for the patient
- Patients in whom the clinician finds antithrombotic therapy contraindicated - prophylaxis included
- Patients at increased risk of bleeding: Surgery in the previous 12 h, expected surgery within 72 h, epidural or spinal puncture in the previous 12 h, platelet count less than 30,000/mm3 in the previous 24 h, INR above 2.0 in the previous 24 h, need of blood products for bleeding in the previous 24 h, treatment with any antithrombotics within 12 h (profylaxis excepted), current or previous intracranial bleeding or traumatic brain or spinal injury within the last month.
Patients requiring any form of antithrombotics (beyond profylaxis) in therapeutic doses or prothrombotics in any dose, including,
- unfractionated heparin within 8 hours before the infusion (prophylactic heparin up to 15,000 U/day permitted).
- Low-molecular-weight heparin within 12 hours (prophylactic doses permitted).
- exceeded the upper limit of normal.
- Acetylsalicylic acid more than 650 mg/day within 3 days before the study.
- Thrombolytic therapy within 3 days before the study (catheter clearance doses permitted).
- Glycoprotein IIb-IIIa antagonists within 7 days before the study.
- Antithrombin III with dose greater than 10,000 U within 12 hours before the study.
- Protein C within 24 hours of the study.
- Previous diagnosed condition that might mimic or complicate the course and evaluation of the infectious disease process (severe bronchiectasis, lung abcess or empyema, aspiration pneumonia, active tuberculosis, pulmonary malignancy, cystic fibrosis, severe chronic interstitial pneumonia, COPD or other forms of chronic lung disease requiring home oxygen treatment or resulting in chronic CO2 retention, , etc.)
- Patient not expected to survive more than 30 days because of uncorrectable medical or surgical condition other than sepsis
- Patient with acute or chronic renal failure requiring dialysis (renal failure without need for dialysis permitted).
- Patient with hematological malignancies of any kind
- Patients who have undergone transplantation of bone marrow, liver, pancreas, heart, lung, or bowel (kidney transplant permitted)
Patient has known hypercoagulable condition:
APC resistance Hereditary protein C, protein S, or antithrombin III deficiency Anticardiolipin or antiphospholipid antibody Lupus anticoagulant Homocysteinemia Recent or highly suspected pulmonary embolism or deep venous thrombosis (within 3 months)
- Patients with known congenital hypocoagulable diseases
- Patient with known AIDS
- Patient with known primary pulmonary hypertension
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Integrilin and Ilomedin given as continous infusion
|
Continuous infusion
Other Names:
|
PLACEBO_COMPARATOR: Standard treatment daily doses of low molecular weight heparin
Standard treatment daily doses of low molecular weight heparin.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in platelet count from baseline to 72 hours post treatment
Time Frame: 11 bloodsamples over 7 days
|
Will be from pre-study drug administration until 7 days
|
11 bloodsamples over 7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Severe bleeding (intracranial or clinical bleeding with the use of 3 RBC units or more) (KyperSept trial)
Time Frame: 7 days
|
If longer in the ICU ward followed until discharged.
|
7 days
|
Days of vasopressor, ventilator and renal replacement therapy and use of blood product (in ICU) after randomization
Time Frame: 7 days
|
Followed longer if not discharged from the ICU at day 7
|
7 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Systemic Inflammatory Response Syndrome
- Inflammation
- Sepsis
- Pneumonia
- Molecular Mechanisms of Pharmacological Action
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Anticoagulants
- Heparin
- Heparin, Low-Molecular-Weight
- Tinzaparin
- Dalteparin
- Eptifibatide
Other Study ID Numbers
- THR-PS-03
- 2011-002254-31 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
King Edward Memorial HospitalCompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated PneumoniaIndia
-
Melinta Therapeutics, Inc.WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
Venatorx Pharmaceuticals, Inc.Biomedical Advanced Research and Development AuthorityNot yet recruitingHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
Hannover Medical SchoolCharite University, Berlin, Germany; University of LeipzigUnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious OrganismsGermany
-
Nantes University HospitalSociété Française d'Anesthésie et de RéanimationCompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired PneumoniaFrance
-
University Medical Centre LjubljanaUniversity of Ljubljana, Faculty of MedicineUnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired PneumoniaSlovenia
-
PfizerCompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)Bulgaria, France, Italy, Korea, Republic of, Mexico, Peru, Poland, Russian Federation, Spain, Turkey, United Kingdom, Vietnam, Philippines, China, Ukraine, Argentina, Brazil, Hungary, Romania, India, Japan, Taiwan, Latvia, Czechia, Slov... and more
-
Arpida AGTerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
ShionogiCompletedHospital Acquired Pneumonia (HAP) | Healthcare-associated Pneumonia (HCAP) | Ventilator Associated Pneumonia (VAP)Israel, Spain, United States, Belgium, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Japan, Latvia, Philippines, Puerto Rico, Russian Federation, Serbia, Taiwan, Ukraine
-
Methodist Health SystemCompletedHospital-acquired Pneumonia | Ventilator-associated PneumoniaUnited States
Clinical Trials on Ilomedin and Integrilin
-
Sisse R. Ostrowski, MD PhD DMScCompletedSeptic ShockDenmark
-
Thrombologic ApSRigshospitalet, Denmark; Lene HolmvangCompletedMyocardial InfarctDenmark
-
Medstar Health Research InstituteTerminatedMyocardial InfarctionUnited States
-
Charite University, Berlin, GermanySchering-PloughTerminatedSystemic SclerosisGermany
-
Assistance Publique - Hôpitaux de ParisCompletedSeptic Shock HyperdynamicFrance
-
University of CincinnatiNational Institute of Neurological Disorders and Stroke (NINDS)CompletedStudy of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-ER)Stroke | Ischemic Stroke | Brain InfarctionUnited States
-
Arthur PancioliNational Institute of Neurological Disorders and Stroke (NINDS)CompletedStroke | Brain InfarctionUnited States
-
Pär JohanssonNot yet recruitingEndothelial Dysfunction | Acute Respiratory Failure | Pulmonary InfectionDenmark
-
Organon and CoDuke Clinical Research InstituteCompletedMyocardial Ischemia | Acute Coronary Syndrome
-
BayerCompleted